Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists.
Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists.
复制标题
DOI：
10.1002/art.24511
复制
发表时间：
2009-05-15
影响因子：
--
通讯作者：
Chiou, Chiun-Fang
中科院分区：
文献类型：
--
作者：
Katz, Patricia;Yelin, Edward;Patel, Vaishali;Huang, Ring-Yue;Chiou, Chiun-Fang
在以社区为基础的RA患者样本中检查自我报告的症状和功能，这些患者是否开始使用生物制剂进行治疗。数据来自于通过社区风湿病学家确定的纵向观察队列的年度电话访谈(1998-2003)。将开始生物治疗(依那西普或英夫利昔单抗)并在两次年度访谈中报告持续使用的受试者(n=，持续使用，CON)与开始生物治疗但停止使用的受试者(n=183)和开始生物治疗但停止使用的受试者(n=42，dison)在开始治疗前一年(基线；对照组为1998年)、治疗第一年和第二年(对照组为1999年和2000年)进行比较。在基线时，服用生物制品的受试者报告说，除疲劳和疼痛严重程度外，所有指标的功能和症状都显著恶化。两年后，HAQ仍有显著差异，但在生物非使用者和CON之间没有其他显著差异。与非使用者相比，DISCON表现出更严重的疼痛程度和更多的关节疼痛。在疼痛关节数(CON：33.4%vs非使用者：16.2%，p=.004)、关节肿胀(38.4%vs 18.7%，p=.003)和晨僵(27.3%vs 10.4%，p=.001)方面，CON的改善比非使用者更频繁。在非使用者和DISCON之间，只有关节肿胀的数量存在差异(36.4%比18.7%，p=0.02)。结果表明，生物治疗是在严重疾病的基础上启动的。在平均17个月的治疗中，Con和非使用者之间的一些但不是全部症状的差异缩小到统计学上不显著的程度。
Examine self-reported symptoms and functioning in a community-based sample of persons with RA who and did not initiate treatment with biologics. Data were from annual telephone interviews (1998–2003) with a longitudinal observational cohort identified through community rheumatologists. Self-reported function and symptoms of subjects who initiated biologic therapy (etanercept or infliximab) and reported consistent use at 2 annual interviews (n=64; “continuous use”, CON) were compared to those with no biologic use (n=183) and those who initiated biologic therapy but discontinued use (n=42, DISCON), at one year prior to initiation of therapy (baseline; 1998 for comparison group), and years 1 and 2 of therapy (1999 and 2000 for comparison group). At baseline, subjects taking biologics reported significantly worse function and symptoms on all measures except fatigue and pain severity. After two years, significant differences in HAQ remained, but there were no other significant differences between biologic non-users and CON. DISCON exhibited significantly greater pain severity and more painful joints than non-users. Improvements from baseline in number of painful joints (CON: 33.4% vs. non-users: 16.2%, p=.004), number of swollen joints (38.4% vs. 18.7%, p=.003), and morning stiffness (27.3% vs. 10.4%, p=.001) were more frequent in CON than non-users. Differences between non-users and DISCON were noted only for number of swollen joints (36.4% vs. 18.7%, p=.02). Results suggest that biologic treatment was initiated based on severe disease. Over an average of 17 months of treatment, differences in some, but not all, symptoms between CON and non-users narrowed to statistical non-significance.
登录
查看更多内容
影响因子：
--
作者：
MASON, JH;ANDERSON, JJ;KAINE, JL
通讯作者：
KAINE, JL
DOI：
10.1002/art.21838
发表时间：
2006-04-15
期刊：
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH
影响因子：
--
作者：
Moreland, LW;Genovese, MC;Singh, A
通讯作者：
Singh, A
影响因子：
--
作者：
FELSON, DT;ANDERSON, JJ;KIESZAK, S
通讯作者：
KIESZAK, S
影响因子：
--
作者：
vanGestel, AM;Prevoo, MLL;vanRiel, PLCM
通讯作者：
vanRiel, PLCM
影响因子：
--
作者：
Finckh, A;Simard, JF;Guerne, PA
通讯作者：
Guerne, PA